Cleveland BioLabs, Inc. (NASDAQ:CBLI)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.50 and traded as high as $1.04. Cleveland BioLabs shares last traded at $1.04, with a volume of 1,391 shares trading hands.
Separately, ValuEngine raised Cleveland BioLabs from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
The firm has a 50 day moving average price of $1.36 and a 200-day moving average price of $1.50.
About Cleveland BioLabs (NASDAQ:CBLI)
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.
Further Reading: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.